176 related articles for article (PubMed ID: 15167634)
1. Pharmacokinetics of 6-mercaptopurine in patients with inflammatory bowel disease: implications for therapy.
Derijks LJ; Gilissen LP; Engels LG; Bos LP; Bus PJ; Lohman JJ; Curvers WL; Van Deventer SJ; Hommes DW; Hooymans PM
Ther Drug Monit; 2004 Jun; 26(3):311-8. PubMed ID: 15167634
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetic effect of adalimumab on thiopurine metabolism in Crohn's disease patients.
Wong DR; Pierik M; Seinen ML; van Bodegraven AA; Gilissen LP; Bus P; Bakker JA; Masclee AA; Neef C; Engels LG; Hooymans PM
J Crohns Colitis; 2014 Feb; 8(2):120-8. PubMed ID: 23932783
[TBL] [Abstract][Full Text] [Related]
3. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease.
Dubinsky MC; Yang H; Hassard PV; Seidman EG; Kam LY; Abreu MT; Targan SR; Vasiliauskas EA
Gastroenterology; 2002 Apr; 122(4):904-15. PubMed ID: 11910342
[TBL] [Abstract][Full Text] [Related]
4. Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.
Gearry RB; Barclay ML; Roberts RL; Harraway J; Zhang M; Pike LS; George PM; Florkowski CM
Intern Med J; 2005 Oct; 35(10):580-5. PubMed ID: 16207256
[TBL] [Abstract][Full Text] [Related]
5. Early Assessment of Thiopurine Metabolites Identifies Patients at Risk of Thiopurine-induced Leukopenia in Inflammatory Bowel Disease.
Wong DR; Coenen MJ; Vermeulen SH; Derijks LJ; van Marrewijk CJ; Klungel OH; Scheffer H; Franke B; Guchelaar HJ; de Jong DJ; Engels LG; Verbeek AL; Hooymans PM;
J Crohns Colitis; 2017 Feb; 11(2):175-184. PubMed ID: 27402913
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of 6-thioguanine in patients with inflammatory bowel disease.
Derijks LJ; Gilissen LP; Engels LG; Bos LP; Bus PJ; Lohman JJ; van Deventer SJ; Hommes DW; Hooymans PM
Ther Drug Monit; 2006 Feb; 28(1):45-50. PubMed ID: 16418693
[TBL] [Abstract][Full Text] [Related]
7. The potential influence of 5-aminosalicylic acid on the induction of myelotoxicity during thiopurine therapy in inflammatory bowel disease patients.
Gao X; Zhang FB; Ding L; Liu H; Wang XD; Chen BL; Bi HC; Xiao YL; Zhao LZ; Chen MH; Huang M; Hu PJ
Eur J Gastroenterol Hepatol; 2012 Aug; 24(8):958-64. PubMed ID: 22664938
[TBL] [Abstract][Full Text] [Related]
8. A prospective evaluation of the impact of allopurinol in pediatric and adult IBD patients with preferential metabolism of 6-mercaptopurine to 6-methylmercaptopurine.
Gerich ME; Quiros JA; Marcin JP; Tennyson L; Henthorn M; Prindiville TP
J Crohns Colitis; 2010 Nov; 4(5):546-52. PubMed ID: 21122558
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic drug monitoring of thiopurine metabolites in adult thiopurine tolerant IBD patients on maintenance therapy.
Gilissen LP; Wong DR; Engels LG; Bierau J; Bakker JA; Paulussen AD; Romberg-Camps MJ; Stronkhorst A; Bus P; Bos LP; Hooymans PM; Stockbrügger RW; Neef C; Masclee AA
J Crohns Colitis; 2012 Jul; 6(6):698-707. PubMed ID: 22398098
[TBL] [Abstract][Full Text] [Related]
10. Utility of measuring 6-methylmercaptopurine and 6-thioguanine nucleotide levels in managing inflammatory bowel disease patients treated with 6-mercaptopurine in a clinical practice setting.
Mardini HE; Arnold GL
J Clin Gastroenterol; 2003; 36(5):390-5. PubMed ID: 12702978
[TBL] [Abstract][Full Text] [Related]
11. Liquid chromatography-tandem mass spectrometry analysis of erythrocyte thiopurine nucleotides and effect of thiopurine methyltransferase gene variants on these metabolites in patients receiving azathioprine/6-mercaptopurine therapy.
Dervieux T; Meyer G; Barham R; Matsutani M; Barry M; Boulieu R; Neri B; Seidman E
Clin Chem; 2005 Nov; 51(11):2074-84. PubMed ID: 16166171
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the use of metabolite measurement in children receiving treatment with a thiopurine.
Armstrong L; Sharif JA; Galloway P; McGrogan P; Bishop J; Russell RK
Aliment Pharmacol Ther; 2011 Nov; 34(9):1106-14. PubMed ID: 21929546
[TBL] [Abstract][Full Text] [Related]
13. Thiopurine maintenance therapy for ulcerative colitis: the clinical significance of monitoring 6-thioguanine nucleotide.
Hanai H; Iida T; Takeuchi K; Arai O; Watanabe F; Abe J; Maruyama Y; Oohata A; Ikeya K; Kageoka M; Miwa I; Yoshirou S; Hosoda Y; Kubota T
Inflamm Bowel Dis; 2010 Aug; 16(8):1376-81. PubMed ID: 20049951
[TBL] [Abstract][Full Text] [Related]
14. Prospective Evaluation of Pharmacogenomics and Metabolite Measurements upon Azathioprine Therapy in Inflammatory Bowel Disease: An Observational Study.
Fangbin Z; Xiang G; Liang D; Hui L; Xueding W; Baili C; Huichang B; Yinglian X; Peng C; Lizi Z; Yanjun C; Feng X; Minhu C; Min H; Pinjin H
Medicine (Baltimore); 2016 Apr; 95(15):e3326. PubMed ID: 27082580
[TBL] [Abstract][Full Text] [Related]
15. Thiopurine methyltransferase genotype-phenotype discordance and thiopurine active metabolite formation in childhood acute lymphoblastic leukaemia.
Lennard L; Cartwright CS; Wade R; Richards SM; Vora A
Br J Clin Pharmacol; 2013 Jul; 76(1):125-36. PubMed ID: 23252716
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis.
Wusk B; Kullak-Ublick GA; Rammert C; von Eckardstein A; Fried M; Rentsch KM
Eur J Gastroenterol Hepatol; 2004 Nov; 16(12):1407-13. PubMed ID: 15618853
[TBL] [Abstract][Full Text] [Related]
17. Influence of 5-aminosalicylic acid on 6-thioguanosine phosphate metabolite levels: a prospective study in patients under steady thiopurine therapy.
de Graaf P; de Boer NK; Wong DR; Karner S; Jharap B; Hooymans PM; Veldkamp AI; Mulder CJ; van Bodegraven AA; Schwab M
Br J Pharmacol; 2010 Jul; 160(5):1083-91. PubMed ID: 20590602
[TBL] [Abstract][Full Text] [Related]
18. Thiopurine dose in intermediate and normal metabolizers of thiopurine methyltransferase may differ three-fold.
Gardiner SJ; Gearry RB; Begg EJ; Zhang M; Barclay ML
Clin Gastroenterol Hepatol; 2008 Jun; 6(6):654-60; quiz 604. PubMed ID: 18467186
[TBL] [Abstract][Full Text] [Related]
19. Monitoring of thiopurine methyltransferase activity in postsurgical patients with Crohn's disease during 1 year of treatment with azathioprine or mesalazine.
Dilger K; Schaeffeler E; Lukas M; Strauch U; Herfarth H; Müller R; Schwab M
Ther Drug Monit; 2007 Feb; 29(1):1-5. PubMed ID: 17304143
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenomics and metabolite measurement for 6-mercaptopurine therapy in inflammatory bowel disease.
Dubinsky MC; Lamothe S; Yang HY; Targan SR; Sinnett D; Théorêt Y; Seidman EG
Gastroenterology; 2000 Apr; 118(4):705-13. PubMed ID: 10734022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
